Percutaneous Biopsy and Drainage of the Lung, Mediastinum, and Pleura


Percutaneous biopsy of focal lung lesions, mediastinal or hilar masses, and pleural or chest wall lesions has become an essential part of staging of pulmonary and extrathoracic tumors.

In the case of lung carcinoma, aspiration biopsy results in a positive diagnosis in 80% to 90% of cases. If a cutting needle is used, a positive diagnosis is expected in 95% to 98% of patients unless the lesion is necrotic. A cutting needle ( Fig. 103.1 ) is generally required for benign lesions because more material is required to allow use of the special stains necessary for the pathologist to make a definitive diagnosis. The attendance of a cytopathologist at biopsy reduces the number of passes needed for diagnosis and avoids the unfortunate necessity for repeated examinations because of an inadequate sample.

Fig. 103.1
Biopsy needles suitable for use in the thorax. Sizes range from 22- to 18-gauge and aspiration to cutting type (lowermost).

With computed tomography (CT) guidance, it is possible to perform a biopsy on almost any portion of the chest with a high degree of safety and minimal morbidity because of the ability to plan a needle path such that major vascular structures are avoided ( Fig. 103.2 ). The smallest needle suitable for the biopsy should be used to reduce complications.

Fig. 103.2
Computed tomography (CT)-guided biopsy. Planning approach with CT allows assessment of the “throw” of a cutting needle. (A) Planning image. (B) Needle in position within mass.

Percutaneous Biopsy of the Lung, Mediastinum, and Pleura

Indications

  • Staging of bronchial carcinoma

  • Diagnosis of focal lung lesions (nodules or consolidation)

  • Diagnosis of metastatic lung lesions

  • Evaluation of chronic infectious diseases when bronchoscopy is unsuccessful

  • Diagnosis of mediastinal masses or lymphadenopathy

  • Diagnosis of focal or diffuse pleural thickening

Contraindications

  • Severe emphysema or insufficient lung capacity in the case of unilateral pneumothorax

  • Bleeding diathesis (international normalized ratio > 1.5 or platelets < 50,000/mm 3 )

  • Uncooperative patients, including those with an intractable cough

  • Positive pressure ventilation, which increases the risk for pneumothorax and bronchopleural fistula

  • Pulmonary arterial hypertension when a central biopsy is contemplated. A cardiothoracic surgeon should be informed of central biopsy where there is potential for pericardial tamponade.

  • Suspected hydatid cyst. There is a possible risk for anaphylaxis if the cyst is intact.

Equipment

  • An appropriate imaging modality (usually a CT scanner but may be a fixed fluoroscopy unit or ultrasound)

  • Informed consent including pneumothorax and hemoptysis

  • Intravenous access

  • Equipment suitable for resuscitation

  • Aspiration needle (Chiba or Westcott, 20–25-gauge)

  • Coaxial needle system (19-gauge outer, 22-gauge inner)

  • Core-cutting needle (spring activated, 18–20-gauge)

  • Cytologist to assess the aspiration sample immediately

  • Microscope, slides, stains, and specimen pots (air and formalin)

  • Percutaneous pneumothorax drainage system

Technique

Anatomy and Approach

Take the shortest possible path to the lesion crossing the least aerated lung avoiding vital structures.

Biopsy of a pleural mass almost always requires a cutting needle and a sample for histologic rather than cytopathologic analysis. If multiple samples are required a coaxial technique should be used.

A direct vertical approach is preferred, with the skin entry site upright. After the biopsy the patient is turned so that the punctured side is lowermost to reduce ventilation of that lung and, the incidence of pneumothorax.

Biopsy of the ribs requires special bone biopsy kits such as the Arrow OnControl (Teleflex, Morrisville, NC) powered bone biopsy system

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here